Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents

Clinical Neurology and Neurosurgery

Volumn 115, Issue SUPPL.1, 2013, Pages

  Tenembaum, Silvia N ^a  

^a Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

Childhood; Disease modifying therapies; Immunosuppressive agents; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; DIPHENHYDRAMINE; ECULIZUMAB; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PARACETAMOL; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT DISEASE; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; BLADDER CARCINOMA; BLOOD CELL COUNT; CARDIAC GRAFT REJECTION; CHILDHOOD DISEASE; CHRONIC ARTHRITIS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CONSTIPATION; CORTICOSTEROID THERAPY; DERMATITIS; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HAIR LOSS; HEADACHE; HEARTBURN; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN A DEFICIENCY; INFECTION; INFLAMMATION; INFUSION RELATED REACTION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALAISE; MENSTRUAL IRREGULARITY; MENTAL INSTABILITY; MONOTHERAPY; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NAUSEA; OBSERVATIONAL STUDY; OSTEOPOROSIS; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; RELAPSE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SIDE EFFECT; SKIN BRUISING; SODIUM RETENTION; SUICIDE ATTEMPT; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VEIN THROMBOSIS; VERTIGO; VOMITING; WEGENER GRANULOMATOSIS;

CHILDHOOD; DISEASE MODIFYING THERAPIES; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA;

ADOLESCENT; AUTOANTIBODIES; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; OPTIC NERVE; TREATMENT OUTCOME;

EID: 84890103077     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2013.09.016     Document Type: Article

References (83)

1. M.P. Amato, B. Goretti, and A. Ghezzi Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up Neurology 75 2010 1134 1140
2. L. Julian, D. Serafin, and L. Charvet Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network J Child Neurol 28 1 2013 102 107
3. A. Ghezzi, V. Deplano, and J. Faroni Multiple sclerosis in childhood: clinical features of 149 cases Mult Scler 3 1997 43 46
4. A. Boiko, G. Vorobeychik, and D. Paty Early onset multiple sclerosis: a longitudinal study Neurology 59 2002 1006 1010
5. T. Chitnis, B. Glanz, and Jaffin Demographics of pediatric onset multiple sclerosis in an MS center population from the Northeastern United States Mult Scler 15 2009 627 631
6. M.P. Gorman, B.C. Healy, and M. Polgar-Turcsanyi Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis Arch Neurol 66 2009 54 59
7. A.J. Thompson, A.T. Toosy, and O. Ciccarelli Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions Lancet Neurol 9 2010 1182 1199
8. F. Barkhof, O.R. Hommes, P. Scheltens, and J. Valk Quantitative MRI changes in gadolinium DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis Neurology 41 1991 1219 1222
9. F. Sellebjerg, D. Barnes, and G. Filippini EFNS guidelines on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses Eur J Neurol 12 2005 939 946
10. R. Zivadinov, M. Zorzon, and R. De Masi Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis J Neurol Sci 267 2008 28 35
11. D. Pohl, and S. Tenembaum Treatment of acute disseminated encephalomyelitis Curr Treat Options Neurol 14 2012 264 275
12. P. Repovic, and F.D. Lublin Treatment of multiple sclerosis exacerbations Neurol Clin 29 2011 389 400
13. D. Pohl, E. Waubant, and B. Banwell Treatment of pediatric multiple sclerosis and variants Neurology 68 16 Suppl 2 2007 S54 S65
14. R.A. Linker, and R. Gold Use of intravenous immunoglobulin and plasma exchange in neurological disease Curr Opin Neurol 21 2008 358 365
15. B.G. Weinshenker, P.C. O'Brien, and T.M. Petterson A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease Ann Neurol 46 1999 878 886
16. M. Keegan, A.A. Pineda, and R.L. McClelland Plasma exchange for severe attacks of CNS demyelination: predictors of response Neurology 58 2002 143 146
17. S.M. Magaña, B.M. Keegan, and B.G. Weinshenker Beneficial plasma exchange response in central nervous system inflammatory demyelination Arch Neurol 68 2011 870 878
18. D. Sato, D. Callegaro, M.A. Lana-Peixoto On behalf of Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS) Treatment of neuromyelitis optica: an evidence based review Arq Neuropsiquiatr 70 1 2012 59 66
19. I. Cortese, V. Chaudhry, and Y. So Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 76 2011 294 300
20. I. Takahashi, Y. Sawaishi, and O. Takeda Childhood multiple sclerosis treated with plasmapheresis Pediatr Neurol 17 1997 83 87
21. S. Schilling, R.A. Linker, and F.B. König Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients Nervenarzt 77 2006 430 438
22. S. Llufriu, J. Castillo, and Y. Blanco Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months Neurology 73 2009 949 953
23. T. Chitnis, S. Tenembaum, and B. Banwell Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis Mult Scler 18 2012 116 127
24. A. Ghezzi, B. Banwell, A. Boyko, M.P. Amato, B. Anlar, and M. Blinkenberg The management of multiple sclerosis in children: a European view Mult Scler 16 2010 1258 1267
25. A.T. Waldman, M.P. Gorman, M.R. Rensel Network of Pediatric Multiple Sclerosis Centers of Excellence of National Multiple Sclerosis Society Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists J Child Neurol 26 6 2011 675 682
26. B. Banwell, A.T. Reder, and L. Krupp Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis Neurology 66 2006 472 476
27. D. Pohl, K. Rostasy, J. Gartner, and F. Hanefeld Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a Neurology 64 2005 888 890
28. S.N. Tenembaum, and M.J. Segura Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis Neurology 67 2006 511 513
29. E. Waubant, J. Hieptas, and T. Stewart Interferon beta-1a in children with multiple sclerosis is well tolerated Neuropediatrics 32 2001 211 213
30. A. Ghezzi, M.P. Amato, and M. Capobianco Treatment of early onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results Neurol Sci 28 2007 127 132
31. A. Ghezzi, M.P. Amato, and P. Annovazzi Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience Neurol Sci 30 2009 193 199
32. S.N. Tenembaum, B. Banwell, D. Pohl On behalf of the REPLAY Study Group Subcutaneous interferon beta-1a in pediatric multiple sclerosis: a retrospective study J Child Neurol 28 7 2013 849 856
33. B. Kornek, G. Bernert, and C. Balassy Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis Neuropediatrics 34 2003 120 126
34. E.A. Yeh, E. Waubant, and L.B. Krupp Multiple Sclerosis therapies in pediatric patients with refractory multiple sclerosis Arch Neurol 68 4 2010 437 444
35. P. Huppke, W. Stark, and C. Zürcher Natalizumab use in pediatric multiple sclerosis Arch Neurol 65 2008 1655 1658
36. G. Borriello, L. Prosperini, and A. Luchetti Natalizumab treatment in pediatric multiple sclerosis: a case report Eur J Paediatr Neurol 13 2009 67 71
37. A. Ghezzi, C. Pozzilli, and L.M. Grimaldi Safety and efficacy of natalizumab in children with multiple sclerosis Neurology 75 10 2010 912 917
38. A. Ghezzi, C. Pozzilli, and L.M.E. Grimaldi Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases Mult Scler 19 8 2013 1106 1112
39. A. Boster, G. Edan, E. Frohman, A. Javed, O. Stuve, and A. Tselis Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician Lancet Neurol 7 2008 173 183
40. N. Makhani, M.P. Gorman, and H.M. Branson Cyclophosphamide therapy in pediatric multiple sclerosis Neurology 72 2009 2076 2082
41. S.L. Hauser, E. Waubant, and D.L. Arnold B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med 358 2008 676 688
42. M. Karenfort, B.C. Kieseier, and D. Tibussek Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis Dev Med Child Neurol 51 2009 159 163
43. J.W. Rose, J.B. Burns, and J. Bjorklund Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results Neurology 69 8 2007 785 789
44. D. Wynn, M. Kaufman, and X. Montalban Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interferon beta Lancet Neurol 9 4 2010 381 390
45. M.P. Gorman, J.M. Tillema, and A.M. Ciliax Daclizumab use in patients with pediatric multiple sclerosis Arch Neurol 69 1 2012 78 81
46. L.B. Krupp, B. Banwell, S. Tenembaum The International Pediatric MS Study Group Consensus definitions proposed for pediatric multiple sclerosis and related disorders Neurology 68 2007 S7 S12
47. L.B. Krupp, M. Tardieu, M.P. Amato The International Pediatric Multiple Sclerosis Study Group International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions Mult Scler 2013 10.1177/1352458513484547
48. B. Banwell, S. Tenembaum, and V.A. Lennon Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders Neurology 70 2008 344 352
49. A. McKeon, V.A. Lennon, and T. Lotze CNS aquaporin-4 autoimmunity in children Neurology 71 2008 93 100
50. D.J. Kimbrough, K. Fujihara, and A. Jacob Treatment of neuromyelitis optica: review and recommendations Mult Scler Relat Disord 1 2012 180 187
51. T.F. Scott, E.M. Frohman, and J. De Seze Evidence-based guideline: clinical evaluation and treatment of transverse myelitis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 77 2011 2128 2134
52. M. Bonnan, and P. Cabre Plasma exchange in severe attacks of neuromyelitis optica Mult Scler Int 2012 10.1155/2012/787630 ID 787630
53. S.H. Kim, W. Kim, and S.Y. Huh Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels J Clin Neurol 9 2013 36 42
54. J.H. Noseworthy, P.C. O'Brien, and T.M. Petterson A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis Neurology 56 2001 1514 1522
55. B.G. Weinshenker, D.M. Wingerchuk, and S. Vukusic Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis Ann Neurol 59 2006 566 569
56. C. Papeix, J.S. Vidal, and J. de Seze Immunosuppressive therapy is more effective than interferon in neuromyelitis optica Mult Scler 13 2 2007 256 259
57. J. Shimizu, Y. Hatanaka, and M. Hasegawa IFNbeta-1b may severely exacerbate Japanese optic-spinal multiple sclerosis in neuromyelitis optica spectrum Neurology 75 2010 1423 1427
58. J. Palace, M.I. Leite, and A. Nairne Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers Arch Neurol 67 8 2010 1016 1017
59. S.H. Kim, W. Kim, and X.F. Li Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 18 10 2012 1480 1483
60. M.H. Barnett, J.W. Prineas, and M.E. Buckland Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy Mult Scler 18 1 2012 108 112
61. A. Jacob, M. Hutchinson, and L. Elsone Does Natalizumab therapy worsen neuromyelitis optica? Neurology 79 2012 1075 1076
62. I. Kleiter, K. Hellwig, and A. Berthele Failure of natalizumab to prevent relapses in neuromyelitis optica Arch Neurol 69 2012 239 245
63. J.H. Min, B.J. Kim, and K.H. Lee Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder Mult Scler 18 2012 113 115
64. J. Sellner, M. Boggild, and M. Clanet EFNS guidelines on diagnosis and management of neuromyelitis optica Eur J Neurol 17 2010 1019 1032
65. R.N. Mandler, W. Ahmed, and J.E. Dencoff Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine Neurology 51 1998 1219 1220
66. C. Costanzi, M. Matiello, and C.F. Lucchinetti Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica Neurology 77 2011 659 666
67. H.L. Pellkofer, M. Krumbholz, and A. Berthele Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab Neurology 76 2011 1310 1315
68. S.H. Kim, W. Kim, and X.F. Li Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years Arch Neurol 68 11 2011 1412 1420
69. J. Boye, T. Elter, and A. Engert An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab Ann Oncol 14 2003 520 535
70. S. Dass, A.C. Rawstron, and E.M. Vital Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis Arthritis Rheum 58 2008 2993 2999
71. T.E. Lotze, J.L. Northrop, and G.J. Hutton Spectrum of pediatric neuromyelitis optica Pediatrics 122 5 2008 e1039 e1047
72. A. Jacob, B.G. Weinshenker, and I. Violich Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients Arch Neurol 65 2008 1443 1448
73. N. Collongues, R. Marignier, and H. Zéphir Long-term follow-up of neuromyelitis optica with a pediatric onset Neurology 75 2010 1084 1088
74. N.A. Mahmood, K. Silver, and K. Onel Efficacy and safety of rituximab in pediatric neuromyelitis optica J Child Neurol 26 2011 244 247
75. E. Kimby Tolerability and safety of Rituximab (MabThera) Cancer Treat Rev 31 6 2005 456 473
76. H.M. Gürcan, D.B. Keskin, and J.N.H. Stern A review of the current use of rituximab in autoimmune diseases Int Immunopharmacol 9 1 2009 10 25
77. M. Kavcic, B.T. Fisher, A.E. Seif, Y. Li, Y.S. Huang, and D. Walker Leveraging administrative data to monitor Rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States J Pediatr 162 6 2013 1252 1258
78. A. Jacob, M. Matiello, and B.G. Weinshenker Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients Arch Neurol 66 2009 1128 1133
79. F. Falcini, S. Trapani, and L. Ricci Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment Rheumatology 45 7 2006 913 915
80. S.J. Pittock, V.A. Lennon, and A. McKeon Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study Lancet Neurol 12 6 2013 554 562
81. N. Djemal, M. Ben Salah, and N. Ben Hlima Devic's neuromyelitis optica in children: a case report and review of the literature Archives de pédiatrie 14 2007 1337 1340
82. I.P. Loma, M.R. Asato, R.A. Filipink, and G. Alper Neuromyelitis optica in a young child with positive serum autoantibody Pediatr Neurol 39 2008 209 212
83. J.A. Peña, M.E. Ravelo, E. Mora-La Cruz, and C. Montiel-Nava NMO in pediatric patients: brain involvement and clinical expression Arq Neuropsiquiatr 69 2011 34 38